BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN BEGIN:VTIMEZONE TZID:Central Standard Time BEGIN:STANDARD DTSTART:20231102T020000 RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11 TZNAME:Central Standard Time TZOFFSETFROM:-0500 TZOFFSETTO:-0600 END:STANDARD BEGIN:DAYLIGHT DTSTART:20230301T020000 RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3 TZNAME:Central Daylight Time TZOFFSETFROM:-0600 TZOFFSETTO:-0500 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION: \;Faculty: \;Elizabeth R. Volkmann\, MD\, MSAssistant Professor of MedicineDirector\, UCLA Scleroderma ProgramCo-Director\, UCLA CTD-ILD ProgramDivision of RheumatologyDepartment of MedicineUniversity o f California\, Los Angeles \;David Geffen School of MedicineLos Angele s\, CADescription: \;After completing this activity\, the participant should be better able to:Assess patient risk factors for progressive SSc-I LDDescribe recommended monitoring for patients with scleroderma and SSc-IL DDevelop appropriate\, evidence-based treatment plans for patients who hav e SSc-ILDSummarize data on emerging agents for the treatment of SSc-ILDThi s activity is provided by Paradigm Medical Communications\, LLC.This activ ity is held in collaboration with the Pulmonary Fibrosis Foundation.Regist er Today \; DTEND:20220223T010000Z DTSTAMP:20240328T124249Z DTSTART:20220223T000000Z LOCATION:Virtual SEQUENCE:0 SUMMARY:New Directions Targeting Inflammatory and Fibrotic Pathways in the Management of SSc-ILD UID:RFCALITEM638472085695048899 X-ALT-DESC;FMTTYPE=text/html:
 \;
Faculty: \;
Elizabeth R. Volkmann\, MD\, MS
Assistant Pr
ofessor of Medicine
Director\, UCLA Scleroderma Program
Co-Director\
, UCLA CTD-ILD Program
Division of Rheumatology
Department of Medici
ne
University of California\, Los Angeles \;
David Geffen School
of Medicine
Los Angeles\, CA
Description: \;
After compl eting this activity\, the participant should be better able to:
This activity is provided by Paradigm Medical Co mmunications\, LLC.
This activity is held in collaboration with the Pulmonary Fibrosis Foundation.< /p>
 \;